May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang

AstraZeneca's VOLGA trial hits EFS and OS incisplatin-ineligible bladder cancer, putting Imfinzi squarely in Keytruda's lane. Plus: Regenxbio's Duchenne gene therapy heads for FDA filing amid safetysignals, a brain tumor linked to a viral vector raises AAV concerns, and biopharma rallies behind Richard Pazdur for FDA commissioner. Also: BMS-Hengrui$15.2B alliance, BeOne's Beqalzi challenges Venclexta, and Taiho's Inqovi expands into AML.visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, AstraZeneca, Imfinzi, durvalumab, bladder cancer, VOLGA, Merck, Keytruda, Padcev, Pfizer,Regenxbio, RGX-202, Duchenne muscular dystrophy, gene therapy, BeOne, Beqalzi, sonrotoclax, Venclexta, Taiho, Inqovi, AML, FDA commissioner, Richard Pazdur,Encoded Therapeutics, Dravet syndrome, ETX101, BMS, Hengrui, Takeda, MacroGenics, BioAge, Isomorphic Labs, Kyverna, Biogen, diranersen, Alzheimer's, ASGCT, Roche, AbbVie